Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases

2015 ASCO Annual Meeting

Published: 31 May 2015

Views: 2474

Rating:

Save

Dr Jan Buckner - Mayo Clinic, Rochester, USA

Dr Buckner presents, at a press conference at ASCO 2015, a federally funded phase III trial that is providing additional information regarding a long-standing discussion about the impact of adjuvant whole brain radiation therapy (WBRT) on cognitive function.

Read the news article and watch the video interview for more.

Related Videos

Intraoperative radiotherapy for brain tumours

Dr Douglas Guedes - Alemão Oswaldo Cruz Hospital, São Paulo, Brazil

Intraoperative radiotherapy for brain tumours ( Dr Douglas Guedes - Alemão Oswaldo Cruz Hospital, São Paulo, Brazil )

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar

Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy

Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Rationale for routine use of IORT for early breast cancer and data for specific indications

Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany

Rationale for routine use of IORT for early breast cancer and data for specific indications ( Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany )

Breast and emerging indications for IORT

Dr David Martinez Perez - AUNA, Lima, Peru

Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

More from ecancer